Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 879 of 6351
-
New hope for tiniest flu patients: IV zanamivir tested in infants under 6 months
Disease control CompletedInfluenza infection is an important public health priority, with seasonal outbreaks and pandemics causing considerable global morbidity and mortality. The PK, pharmacodynamics (PD), safety and efficacy of IV zanamivir have been evaluated in adults, adolescents and infants more th…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Quick-Clot powder could save lives in severe trauma bleeding
Disease control CompletedAnnually over 7000 Australians are treated for severe trauma. Haemorrhage secondary to severe trauma is a major cause of potentially preventable death and poor outcomes in Australian adults. Severe trauma may trigger changes in blood clotting mechanisms and factor levels leading …
Phase 3 • Sponsor: Australian and New Zealand Intensive Care Research Centre • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug aims to lower dangerous fat levels in the blood
Disease control CompletedThe purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in participants with hypertriglyceridemia and atherosclerotic cardiovascular disease, or with severe hypertriglyceridemia.
Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Prostate cancer patients may get a break from hormone shots
Disease control OngoingThis phase II trial examines antiandrogen therapy interruptions in patients with hormone-sensitive prostate cancer that has spread to other places in the body (metastatic) responding exceptionally well to androgen receptor-pathway inhibitor therapy. The usual treatment for patien…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Promising targeted therapy for tough brain cancers moves forward
Disease control Recruiting nowThis study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks…
Phase 1/2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New sublingual film aims to calm agitation at home for mental health patients
Symptom relief CompletedIn this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.
Phase 3 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Could a single MRI-Guided biopsy replace the standard battery?
Diagnosis CompletedThe goal of this clinical trial is to assess the concordance of treatment decisions made in multidisciplinary consultation meeting based on targeted biopsies alone or targeted biopsies associated with systematic biopsies in patients with suspected prostate cancer.
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Diagnosis
Last updated Aug 22, 2026 00:00 UTC
-
One shot for knee pain? trial tests a new injection for osteoarthritis
Symptom relief CompletedThis phase 3 study was a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target (most painful) knee joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg loreci…
Phase 3 • Sponsor: Biosplice Therapeutics, Inc. • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Could a lower dose of a transplant drug be better for blood cancer patients?
Disease control Recruiting nowBackground: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers. Sometimes these transplants cause serious side effects, including a common immunologi…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New epilepsy drug shows promise in final stage trial
Disease control CompletedThe X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Phase 3 • Sponsor: Xenon Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New lung cancer combo shows promise in Head-to-Head trial
Disease control OngoingThis is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: *…
Phase 3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental combo aims to tame aggressive lymphoma without chemo
Disease control OngoingTo learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.
Early phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Decades-Old drug reverse pancreatic scarring?
Disease control OngoingChronic pancreatitis is a rare but debilitating condition associated with chronic abdominal pain, diarrhea, diabetes, and an 8-fold increased risk for the development of pancreatic cancer. Unfortunately, there is no available treatment to prevent the progression of chronic pancre…
Phase 1/2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Veterans' PTSD may be soothed by a simple neck injection
Symptom relief OngoingPosttraumatic Stress Disorder (PTSD) is a debilitating condition that affects about 15% of Veterans. Current treatments for Veterans with PTSD include medications and psychological therapies that help to process and desensitize to traumatic events. While effective for many, these…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Could a vaccine keep triple negative breast cancer from returning?
Vaccine OngoingThis phase II trial studies the effect of DNA plasmid based vaccine (STEMVAC) in treating patients with patients with stage IB-III triple negative breast cancer. STEMVAC may wake up the immune system in patients who have had a diagnosis of triple negative breast cancer and have b…
Phase 2 • Sponsor: University of Washington • Aim: Vaccine
Last updated Jul 25, 2026 00:00 UTC
-
New combo therapy targets rare childhood and adult cancers
Disease control OngoingThis phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cel…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Heart shunt device put to the test in 750-Patient Sham-Controlled trial
Disease control OngoingMulticenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
Sponsor: Corvia Medical • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo aims to fight recurrent brain tumors
Disease control Recruiting nowThis is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a robust anti-tumor immune res…
Phase 2 • Sponsor: Stephen Bagley, MD, MSCE • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a Muscle-Building drug boost weight loss? new trial tests bimagrumab with semaglutide
Disease control CompletedA phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug shows promise for slowing lung scarring in major trial
Disease control CompletedThis study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study. If they already take nintedanib, they can continue treatment throughout the study. Th…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC